Publication:
Anti-lymphocyte, anti-monocyte, and anti-endothelial cell antibodies in chronic haemodialysis patients

Simple item page
dc.contributor.authorDİRESKENELİ, RAFİ HANER
dc.contributor.authorsDireskeneli H., Özgön S., Özener C., Lawrence R., Erman M., Sarsmaz N., Akoglu E.
dc.date.accessioned2022-03-15T01:52:57Z
dc.date.accessioned2026-01-10T20:48:18Z
dc.date.available2022-03-15T01:52:57Z
dc.date.issued1992
dc.description.abstractPatients receiving chronic haemodialysis treatment are known to have a high prevalence of anti-panel antibodies (anti-lymphocyte, antimonocyte, and anti-endothelial cell) originating from a number of different possible sensitizing events such as blood transfusions, multiparity, or renal transplantation. © 1992 European Dialysis and Transplant Association-European Renal Association.
dc.identifier.doi10.1093/oxfordjournals.ndt.a092160
dc.identifier.issn9310509
dc.identifier.pubmed1321378
dc.identifier.urihttps://hdl.handle.net/11424/246204
dc.language.isoeng
dc.relation.ispartofNephrology Dialysis Transplantation
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectChronic haemodialysis
dc.subjectPanel-reactive antibodies
dc.subjectSensitization
dc.subjectTransfusion
dc.titleAnti-lymphocyte, anti-monocyte, and anti-endothelial cell antibodies in chronic haemodialysis patients
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage426
oaire.citation.issue5
oaire.citation.startPage422
oaire.citation.titleNephrology Dialysis Transplantation
oaire.citation.volume7

Files

Collections

Araştırma Çıktıları